Get started
RocketTickers

FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic

Long
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)  
RocketTickers  
NASDAQ:REGN   Regeneron Pharmaceuticals, Inc.
Beyond Technical Analysis
0
0
beyondta
REGN: Regeneron Pharmaceuticals, Inc.
2019-03-11 15:44:00
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents - PR Newswire
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.